Physician profile
Elina Levkoff
NPI 1376973156
$3,516.02
in general payments reported to CMS, 2019-2025
43 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $132 · 2021: $398 · 2022: $206 · 2023: $574 · 2024: $829 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $477.62 | 2021-2025 | |
| Pfizer INC. | $266.05 | 2024-2025 | |
| Amgen INC. | $260.90 | 2019-2025 | Repatha, Repatha, Otezla |
| Ucb, INC. | $224.49 | 2024-2025 | Zilbrysq, Rystiggo |
| Alexion Pharmaceuticals, INC. | $179.45 | 2023-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $176.05 | 2021-2025 | Vyepti |
| Novo Nordisk INC | $134.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Acorda Therapeutics, INC | $133.32 | 2019-2024 | Inbrija, Ampyra |
| Argenx US, INC. | $116.97 | 2022-2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $110.33 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $97.82 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $84.83 | 2023-2025 | Hyqvia, Gammagard |
| Horizon Therapeutics Plc | $81.79 | 2019 | |
| Neurelis, INC. | $78.74 | 2021-2025 | Valtoco |
| Genentech USA, INC. | $78.29 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elina Levkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.